drugset / Trial / NCT01216397

Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers

NCT01216397

Phase 1 Completed 40 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the current study is to investigate the relative bioavailability of two different batches of a 2.5 mg linagliptin / 1000 mg metformin fixed dose combination tablet (FDC).

Timeline

Start
2010-09
Primary completion
2010-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 2.5 mg
Subject Metformin Small molecule 1000 mg

Indications

No indication recorded.